Routine versus clinically driven laboratory monitoring and fi rst-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial

The Lancet

Volumn 381, Issue 9875, 2013, Pages 1391-1403

  Gibb, Diana M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ADOLESCENT DISEASE; AFRICA; AGE DISTRIBUTION; ARTICLE; BIOCHEMISTRY; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; COMPUTER ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGICAL PARAMETERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LABORATORY MONITORING; MAJOR CLINICAL STUDY; MALE; MONITORING; OPEN STUDY; PARALLEL DESIGN; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; ZIMBABWE;

EID: 84876280807     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62198-9     Document Type: Article

References (40)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-10.
2. Institute for Health Metrics and Evaluation. Financing global health 2011: continued growth as MDG deadline approaches. http://www. healthmetricsandevaluation.org/publications/policy-report/financing-global- health-2011-continued-growth-mdg-deadline-approaches (accessed Oct 25, 2012).
3. UNAIDS. World AIDS Day report 2012. Geneva: UNAIDS, 2012.
4. Abongomera G, Namata H, Nkhata M, et al. Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe. XIX International AIDS Conference; Washington DC, USA; July 22-27, 2012; abstr LBPE572012.
5. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-31.
6. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; Feb 27-March 2, 2011; abstr 44.
7. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825-33.
8. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.
9. HIV Paediatric Prognostic Markers Collaborative Study Group (HPPMCS). Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 1605-11.
10. HIV Paediatric Prognostic Markers Collaborative Study Group (HPPMCS). Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006;20: 1289-94.
11. Cross Continents Collaboration for Kids (3Cs4kids). Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22: 97-105.
12. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-64.
13. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2: 93-102.
14. Judd A. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS 2011; 25: 2279-87.
15. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization, 2006.
16. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11: 741-49
17. National Institutes of Health Division of AIDS. Division of AIDS table for grading the severity of adverse events. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2004 (clarification 2009).
18. National Institutes of Health Division of Microbiology and Infectious Diseases (DMID) pediatric toxicity tables. http://www. niaid.nih.gov/ LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf (accessed Feb 11, 2013).
19. Kasirye P, Kendall L, Adkison KK, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther 2012; 91: 272-80.
20. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once-versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15: 1115-24.
21. WHO. Annex E: prescribing information and weight-based dosing of available ARV formulations for infants and children. Geneva: World Health Organization, 2010.
22. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Clinical safety data management: definitions and standards for expedited reporting (E2A). London: European Medicines Agency, 1994.
23. Paediatric European Network for the Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359: 733-40.
24. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994;13: 2359-67.
25. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PloS One 2012;7: e33672.
26. Violari A, Cotton M, Otwombe K, et al. Does early initiation of ART in infants affect virologic and resistance outcomes? Data from the CHER trial after 6 years of follow up. HIV11 Congress; Glasgow, UK; Nov 11-14; abstr 0224.
27. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21: 947-55.
28. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-89.
29. Prendergast AJ, Penazzato M, Cotton M, et al. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med 2012; 9: e1001273.
30. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11: 273-83.
31. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis 2011; 51: 1081-89.
32. Nahirya-Ntege P, Musiime V, Naidoo B, et al. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J 2010; 30: 535-37.
33. Oudijk JM, McIlleron H, Mulenga V, et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS 2012; 26: 1523-28.
34. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47: 566-69.
35. Munderi P, Walker AS, Kityo C, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 2010; 11: 334-44.
36. Musiime V, Kaudha E, Kayiwa J, et al. Antiretroviral drug resistance profiles and response to second-line therapy among HIV-1 infected Ugandan children. AIDS Res Hum Retroviruses 2013; published online Jan 11. DOI:10.1089/aid.2012.0283.
37. Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55: 1707-18.
38. Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009; 49: 336-43.
39. Walker AS, Gibb DM. Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis 2011; 24: 27-33.
40. Gilks CF, Walker AS, Munderi P, et al. A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria. PloS One (in press).